Brainsway (NASDAQ:BWAY) Price Target Raised to $19.00 at Northland Securities

Brainsway (NASDAQ:BWAY) had its price objective boosted by Northland Securities from $15.00 to $19.00 in a report issued on Thursday morning,Benzinga reports. Northland Securities currently has an outperform rating on the stock.

BWAY has been the topic of several other research reports. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. HC Wainwright reissued a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Brainsway in a research note on Thursday.

Brainsway Price Performance

BWAY opened at $12.83 on Thursday. Brainsway has a 12 month low of $7.06 and a 12 month high of $13.65. The business has a fifty day moving average price of $12.03 and a 200 day moving average price of $10.51. The stock has a market capitalization of $242.49 million, a price-to-earnings ratio of 49.35 and a beta of 1.42.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.03. The company had revenue of $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway had a return on equity of 9.43% and a net margin of 11.60%. On average, research analysts anticipate that Brainsway will post 0.08 earnings per share for the current year.

Hedge Funds Weigh In On Brainsway

A number of large investors have recently bought and sold shares of the business. Valor Management LLC bought a new stake in shares of Brainsway during the fourth quarter valued at approximately $19,838,000. Eagle Global Advisors LLC acquired a new position in Brainsway in the first quarter worth approximately $590,000. MYDA Advisors LLC grew its position in Brainsway by 100.2% during the 4th quarter. MYDA Advisors LLC now owns 120,100 shares of the company’s stock worth $1,133,000 after purchasing an additional 60,100 shares in the last quarter. Two Sigma Advisers LP grew its position in Brainsway by 32.6% during the 4th quarter. Two Sigma Advisers LP now owns 60,600 shares of the company’s stock worth $571,000 after purchasing an additional 14,900 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in shares of Brainsway during the 1st quarter valued at $129,000. Institutional investors own 30.11% of the company’s stock.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.